Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zibotentan dose-escalation in metastatic prostate cancer
NCT00055471Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2003
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zibotentan in Metastatic Prostate Cancer (mPC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Dose Limiting Toxicities at Day 29. Started Jun 2003; status: completed.
02
Drugs
zibotentan
03
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT00055471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055471.